ACE and diabetes mellitus: Our findings contrast in part to those by Jellis et al in which patients with diabetes mellitus treated with spironolactone failed to show a reduction in ECV.40 This result may be explained by the high use of ACE inhibitors at baseline, exclusion of patients without diastolic dysfunction, and the use of a now‐outdated pulse sequence for the estimation of myocardial ECV.